Omnimoxa (Moxifloxacin Hydrochloride)

Moxifloxacin Hydrochloride, the active ingredient in Omnimoxa, is a fluoroquinolone antibiotic presented as a 0.5% ophthalmic solution for topical ocular use. It treats bacterial eye infections such as conjunctivitis and keratitis in adult and pediatric patients. GNH USA supplies Omnimoxa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, ophthalmology clinics and pharmacies worldwide.

Omnimoxa is a fluoroquinolone antibiotic that targets bacterial pathogens in ocular tissues. - Bacterial conjunctivitis: Reduces bacterial load and accelerates healing of the conjunctiva. - Bacterial keratitis: Eliminates pathogenic bacteria to prevent corneal damage and preserve vision. - Post‑surgical prophylaxis: Helps prevent infection after eye surgery such as cataract extraction.

Adverse reactions to Omnimoxa are generally mild and related to local ocular irritation.

Common Side Effects: - Eye irritation: Stinging or burning sensation upon instillation. - Redness: Conjunctival hyperemia. - Tearing: Increased lacrimation. - Foreign‑body sensation: Feeling of grit in the eye. - Blurred vision: Temporary visual disturbance after dosing.

Serious or Rare Side Effects: - Corneal ulceration: Development of a corneal lesion. - Anaphylaxis: Severe allergic reaction with systemic symptoms. - Stevens‑Johnson syndrome: Rare mucocutaneous disorder. - Toxic keratopathy: Damage to corneal epithelium. - Vision loss: Sudden decrease in visual acuity.

When using Omnimoxa, consider the following safety measures: - Contraindication: Do not use in patients with known hypersensitivity to moxifloxacin or other fluoroquinolones. - Caution in corneal disease: Use carefully in patients with compromised corneal epithelium. - Monitor pediatric use: Adjust monitoring for children as safety data are limited. - Avoid contact lens wear: Discontinue lenses before and after instillation to prevent drug absorption. - Store below 25°C: Keep in the original container, protect from light and moisture.

Omnimoxa may interact with other ophthalmic preparations and systemic medications.

Major Interactions (Avoid): - Anticholinergic eye drops: May reduce ocular absorption of moxifloxacin. - Corneal anesthetics: Increased risk of corneal toxicity when combined.

Moderate Interactions (Monitor Closely): - Systemic fluoroquinolones: Additive risk of tendon toxicity. - Non‑steroidal anti‑inflammatory eye drops: May enhance local irritation. - Corticosteroid eye drops: Potential for delayed wound healing.